Lorbrena 25 mg/1 (Lorlatinib TABLET, FILM COATED) 25 mg/1

Lorbrena 25 mg is a medication used to treat specific types of cancer. This oral tablet, manufactured by Pfizer, contains lorlatinib as its active ingredient.

Strength

25 mg/1

Pack Size

120 TABLET, FILM COATED in 1 BOTTLE (0069-0227-03)

Manufacturer / TM Owner

Pfizer Laboratories Div Pfizer Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lorbrena 25 mg is primarily used in the treatment of certain types of cancer. It works by targeting specific proteins involved in cancer cell growth. Patients often wonder, 'What is Lorbrena used for?' This medication is typically prescribed for advanced or metastatic cancers that have progressed despite other treatments.

Side Effects

Common effects of Lorbrena 25 mg may include fatigue, nausea, and dizziness. Some users also report changes in taste or vision. These effects can vary widely among individuals and are not experienced by everyone taking the medication.

Precautions & Warnings

Lorbrena 25 mg should be handled with care. It is important to follow the advice of a healthcare provider regarding its use. Patients should be aware of potential side effects and discuss any concerns with their doctor before starting treatment.

Avoid Interactions

Lorbrena 25 mg may interact with other medications, including those metabolized by the liver. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain foods may also affect how this medication works.

References

Frequently Asked Questions

Lorbrena 25 mg is used to treat specific types of cancer, particularly those that have progressed despite other treatments.

Lorbrena 25 mg is taken orally, typically as prescribed by a healthcare provider. Always follow the instructions provided by your doctor.

Common side effects may include fatigue, nausea, dizziness, and changes in taste or vision. Not everyone experiences these effects.

Lorbrena 25 mg may interact with other medications. It is important to discuss all medications with your healthcare provider to avoid potential interactions.

Precautions include following the advice of a healthcare provider, being aware of potential side effects, and discussing any concerns with your doctor before starting treatment.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.